Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 8Plasma cell 5Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 84pembrolizumab 69Pemetrexed 62Cisplatin 52Paclitaxel 30Docetaxel 29atezolizumab 28durvalumab 25Specimen Handling 25Nivolumab 24Magnetic Resonance Spectroscopy 20osimertinib 18Gemcitabine 18130-nm albumin-bound paclitaxel 18Etoposide 16Cetuximab 14Radiotherapy 13Platinum 12Taxes 10Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8Radiation 8Ipilimumab 8fludarabine 7Ramucirumab 7PM 01183 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
dexamethasone 21-phosphate × Thoracic × 30 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡